<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928471</url>
  </required_header>
  <id_info>
    <org_study_id>137.03</org_study_id>
    <nct_id>NCT02928471</nct_id>
  </id_info>
  <brief_title>Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss</brief_title>
  <acronym>IM-LOSEIT-I</acronym>
  <official_title>Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss, Investigating the Impact on Inflammation (A Substudy to &quot;Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial&quot; (NCT02905864)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Gudbergsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parker Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a substudy to a randomised trial investigating the effect of liraglutide on body
      weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In
      the parent trial, patients will be subjected to an 8-week diet intervention phase including a
      low-calorie diet and dietetic counseling, after which. Patients will be randomised to receive
      either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on
      re-introducing regular foods and a focus on continued motivation to engage in a healthy
      lifestyle.

      This substudy aims to investigate any changes in MRI associated with the initial 8-week
      weight loss intervention, and the value of CT scans in predicting the effect of weight loss.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the degree of inflammation in the knee-joint (DCE-MRI)</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Change will be assessed via a dynamic contrast enhanced MRI evaluation of corpus hoffa (Ballegaard C et al. and Riis RG et al.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the degree of inflammation in the knee-joint (CE-MRI)</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Change will be assessed via a static contrast enhanced MRI evaluation of the level of synovitis in the knee-joint (11 sites scored 0-2, ad modum Guermazi et al.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the degree of inflammation in the knee-joint (MRI)</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Change will be assessed via a conventional MRI evaluation of the level of synovitis and effusion (combined) in the knee-joint (MOAKS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cartilage composition</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Change will be assessed via T2-maps of cartilage in the weight-bearing parts of the knee-joint (ROI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone marrow lesions (BML)</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Change will be assessed via the MRI knee scoring system MOAKS; BML sum-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of clinical symptoms (KOOS pain) by the level of crystal deposition on dual-energy CT at week 0</measure>
    <time_frame>Week 0</time_frame>
    <description>Crystal deposition will be evaluated via dual-energy CT</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Intensive dietary intervention</arm_group_label>
    <description>Supervised dietary weight loss program lasting 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intensive dietary intervention</intervention_name>
    <description>Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.</description>
    <arm_group_label>Intensive dietary intervention</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants eligible for parent trial (NCT02905864), i.e. overweight/obese individuals
        with knee osteoarthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Same as parent trial (NCT02905864)

        Further Exclusion Criteria

          -  Same as parent trial (NCT02905864)

          -  Usual exclusion criteria for MRI (i.e. pacemakers etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Henrik R Gudbergsen, MD, PhD</last_name>
    <phone>+45 29 84 28 88</phone>
    <email>henrik.rindel.gudbergsen.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikael Boesen, MD, PhD</last_name>
    <phone>+45 38 16 46 54</phone>
    <email>mikael.ploug.boesen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Parker Institute and Department of Radiology at Bispebjerg and Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <state>Capital Region</state>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Boesen, MD, PhD</last_name>
      <phone>+45 38 16 46 54</phone>
      <email>mikael.ploug.boesen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>henrik r gudbergsen, MD, PhD</last_name>
      <phone>+45 29 84 28 88</phone>
      <email>henrik.rindel.gudbergsen.01@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Parker Research Institute</investigator_affiliation>
    <investigator_full_name>Henrik Gudbergsen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Liraglutide</keyword>
  <keyword>Liraglutide 3 mg</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Obesity</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Computed tomography</keyword>
  <keyword>Dynamic contrast enhanced MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

